Wells Fargo
ARTV

Wells Fargo’s Artiva Biotherapeutics ARTV Stock Holding History

Wells Fargo’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$53.2K Buy
5,480
+3,980
+265% +$36.2K ﹤0.01% 5699
2026
Q1 		$9.66K Hold
1,500
– – ﹤0.01% 5976
2025
Q4 		$6.43K Sell
1,500
-200
-12% -$755 ﹤0.01% 6039
2025
Q3 		$4.88K Sell
1,700
-364
-18% -$974 ﹤0.01% 6079
2025
Q2 		$3.12K Sell
2,064
-10,595
-84% -$22.3K ﹤0.01% 6151
2025
Q1 		$38K Buy
12,659
+4,043
+47% +$21.8K ﹤0.01% 5489
2024
Q4 		$86.8K Buy
8,616
+3,361
+64% +$40.4K ﹤0.01% 5274
2024
Q3 		$81.2K Buy
+5,255
New +$60.9K ﹤0.01% 5136

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

Wells Fargo's ARTV Position: Q2 2026 in Review

Wells Fargo increased its Artiva Biotherapeutics (ARTV) stake by 265% in Q2 2026, buying an estimated $36.2K and bringing the position to 5,480 shares worth $53.2K. The position accounts for ﹤0.01% of the portfolio, ranked #5699.

Wells Fargo first reported a position in ARTV in Q3 2024 and has held it in 8 quarters since. The position peaked at $86.8K in Q4 2024. 72 funds tracked by Wall St. Rank hold ARTV as of Q2 2026.

  • Wells Fargo held 5,480 shares of Artiva Biotherapeutics worth $53.2K as of Q2 2026.
  • Wells Fargo bought 3,980 Artiva Biotherapeutics shares in Q2 2026, an estimated $36.2K.
  • Artiva Biotherapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #5699 holding.
  • Wells Fargo first reported a position in Artiva Biotherapeutics in Q3 2024 and has held it in 8 quarters since.
  • Wells Fargo's Artiva Biotherapeutics position peaked at $86.8K in Q4 2024.
  • 72 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.